Journal article
B.07 Review of patients with Spinal Muscular Atrophy treated with Nusinersen in Ontario
Abstract
Background:
Spinal Muscular Atrophy (SMA) is an autosomal recessive neurodegenerative disease. In June 2017, Health Canada approved Nusinersen, currently the only available drug for SMA. Since 2016, patients in Ontario have been treated clinically with Nusinersen through different access programs.
Authors
Remtulla S; Zapata-Aldana E; Gonorazky H; Boyd J; Scholtes C; Hicks R; Leung A; Dowling J; Vajsar J; McMillan H
Journal
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, Vol. 45, No. s2, pp. s13–s13
Publisher
Cambridge University Press (CUP)
Publication Date
June 2018
DOI
10.1017/cjn.2018.95
ISSN
0317-1671